OFI Invest Asset Management Has $42.01 Million Position in Gilead Sciences, Inc. $GILD

OFI Invest Asset Management lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 92.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 378,473 shares of the biopharmaceutical company’s stock after acquiring an additional 182,243 shares during the period. OFI Invest Asset Management’s holdings in Gilead Sciences were worth $42,011,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in Gilead Sciences in the second quarter valued at approximately $2,150,268,000. Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after acquiring an additional 5,392,191 shares in the last quarter. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. boosted its stake in Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in Gilead Sciences in the second quarter worth $238,083,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $124.16 on Tuesday. The firm has a market capitalization of $154.04 billion, a P/E ratio of 19.25, a P/E/G ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The stock has a 50 day moving average price of $122.47 and a two-hundred day moving average price of $116.31. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the company earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the sale, the insider owned 106,221 shares in the company, valued at approximately $12,958,962. This trade represents a 2.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 136,257 shares of company stock valued at $16,723,492 over the last 90 days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GILD shares. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a report on Friday, October 31st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Daiwa Capital Markets increased their price target on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $131.54.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.